Slides
Page 1
First Quarter FY 2027 Earnings Results October 8, 2026
Page 2
Forward looking statements 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “projects,” “believes,” “seeks,” “estimates,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2026. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason. Notice Regarding Non-GAAP Financial Measures Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics’ business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported adjusted EBITDA (income before interest, taxes, depreciation and amortization and stock-based compensation); adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics’ performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics’ underlying business. Management encourages investors to review AngioDynamics’ financial results prepared in accordance with GAAP to understand AngioDynamics’ performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics’ financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.
Page 3
3 Leadership Transition Eric Honroth named President and Chief Executive Officer, succeeding Jim Clemmer •Eric Honroth appointed President and Chief Executive Officer and a member of the Board of Directors, effective November 2, 2026, succeeding Jim Clemmer •Follows a comprehensive Board-led search process •Brings more than 20 years of leadership experience in medical devices and life sciences •Proven track record of driving double-digit growth and profitability across large, global organizations •Background spans cardiovascular, endovascular, urology, and oncology, directly aligned with AngioDynamics' markets •Jim Clemmer to remain with the Company as an executive advisor
Page 4
4 Q1 FY 2027 Key Takeaways Continued commercial and operational execution drives AngioDynamics’ accelerated and profitable growth. Total +6.9% YoY Revenue Growth Med Tech +13.2% Med Device +1.4% Auryon +14.7% Med Tech YoY Revenue Growth Mech Thrombectomy 6.7% NanoKnife Probes +24.1% Focus on Profitability Balance Sheet Strength •Ended quarter with $34M in Cash •Zero debt with flexibility of revolving line of credit •Used ~$15.3M of cash from operations in the quarter, in line with historical trends •Will generate positive cash flow from operations in FY27 •Adjusted EBITDA of $5.0M Continued Execution •Net sales of $80.9M, +6.9% YoY growth •Med Tech segment sales of $39.9M, +13.2% YoY growth •Med Device segment sales of $41.0M, +1.4% YoY growth
Page 5
5 Q1 FY 2027 Financial Snapshot $40.4 $41.0 $35.3 $39.9 $75.7 $80.9 Q1 26 Q1 27 Net Sales Med Device Med Tech +1.4% Growth +13.2% Growth Segment Revenue Contribution 53% 47% Q1 26 Med Device Med Tech 51% 49% Q1 27 Med Device Med Tech Segment Gross Margin 52.7% 66.2% Med Device Med Tech
Page 6
$145 $151 $157 $161 $165 $166 $170 $41 $56 $79 $96 $106 $127 $150 $186 $206 $235 $257 $271 $293 $320 FY20 A FY21 A FY22 A FY23 A FY24 A FY25 A FY26 A Pro Forma Fiscal Year Net Sales ($M) Med Device Med Tech 6 Demonstrated Med Tech Growth Execution 6 Med Tech ~22% of Total Med Tech ~47% of Total
Page 7
7 Q1 FY 2027 MedTech Performance Snapshot •Auryon: Double-digit growth for the 21st straight quarter, driven by our hospital atherectomy shift, customer base expansion, and early international adoption. •Mechanical Thrombectomy: Strong demand for AlphaVac and AngioVac, with continued progress on AlphaReturn and our infective endocarditis study, both IDE-approved. •NanoKnife: Strong growth on record prostate volumes and probe demand, supported by expanding reimbursement coverage following last quarter's positive Medicare decision. YoY GrowthSales ($M)Q1 FY 2027 14.7%$18.9Total Auryon YoY GrowthSales ($M)Q1 FY 2027 37.4%$4.5AlphaVac -5.9%$7.5AngioVac 6.7%$12.0Total Mech Thromb. -36.0%$0.7Unifuse 3.0%$12.7Total Thrombus Mgmt. YoY GrowthSales ($M)Q1 FY 2027 24.1%$6.7Disposables 53.5%$1.7 Capital 29.0%$8.3 Total NanoKnife +13.2% growth driven by solid commercial execution and continued portfolio adoption Key Highlights
Page 8
8 Fiscal Year 2027 Guidance supported by balance sheet strength $320 $336 - $341 FY 2026 A FY 2027 G Net Sales ($M) Med Device Med Tech *Guidance was reiterated in conjunction with fiscal Q1 FY 2027 earnings call on October 8, 2026 +12 - 15% Med Tech Current GuidanceMetric $336.0M - $341.0MNet Sales +12% - 15%Med Tech Net Sales Growth FlatMed Device Net Sales Growth 54% – 55%Gross Margin +$13.0M - $16.0MAdjusted EBITDA ($0.29) – ($0.24)Adjusted EPS Flat Med Device FY 2027 Financial Guidance* Med Tech ~50% of Total
Page 9
9 Appendix
Page 10
10 Reconciliation of Net Loss and Diluted Loss Per Share to Non-GAAP Adjusted Net Loss and Diluted Loss Per Share (in thousands, except per share data) Reconciliation of Net Loss to Adjusted EBITDA (in thousands)
Page 11
11 Detail of “Acquisition, Restructuring and Other Items, net” (in thousands)